Q1 2025 Management View CEO Phillip Chan reported that CytoSorbents is focused on three main areas: the performance and growth catalysts of the core CytoSorb business, regulatory status and plans for ...

BioCardia, Inc. ( NASDAQ: BCDA) Q1 2025 Earnings Conference Call May 14, 2025, 16:30 PM ET Peter Altman - President and CEO David McClung - CFO Miranda Peto - IR Joe Pantginis - H.C. Wainwright Laura ...

The latest health news highlights Sanofi's $20 billion U.S. investment through 2030, Merck's cancer drug expansion and the ...

Reuters, the news and media division of Thomson Reuters, is the world’s largest multimedia news provider, reaching billions ...

This follows what appeared to be a generally positive data readout for belrestotug at ESMO 2024 just a few months ago.

The FDA did not respond to a request for comment. U.S. Health Secretary Robert F. Kennedy Jr. has said that the agency's ...

Received a "Study May Proceed” letter from the FDA for the Phase 2 trial for the treatment of FAP. This trial, run by CP-CTNet and financially supported by the NCI's Division of Cancer Prevention, ...

DUBLIN, May 13, 2025 - Avadel Pharmaceuticals plc (Nasdaq: AVDL), a biopharmaceutical company focused on transforming medicines to transform lives, today announced the appointment of Susan Rodriguez ...

Cytokinetics' PDUFA date for aficamten was extended to December 26th of 2025, due to the FDA's need to review a submitted ...

FDA seeking 'aggressive' adoption of AI . The FDA announced an "aggressive timeline" to deploy artificial intelligence ...

Although these factors will affect Omron's free cash flow generation in fiscal 2024, we expect this to be temporary and the company's financial health to return to its normal state over the medium ...

Information technology and pharma sector, Tata Steel Ltd., and Hindalco Ltd. were among the top companies on brokerages' ...